Early Rabies Vaccine Immunization in Primary School Children (I49P1)
Compare Immunogenicity, Safety and Long-term Booster Response After Primary Vaccination With 2 Intradermal Doses Versus 3 Intradermal Doses of PCEC Rabies Vaccine (Rabipur) in Healthy School Children in Thailand (5-8 Years of Age)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Phetchabun, Thailand
- Phetchabun Province primary schools
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Male and female 5-8 years old school children will be included in the study if:
- Their parents or legal guardians have given the written informed consent prior to study entry;
- They are in good health at time of study entry as determined by medical history, physical examination and clinical judgment of the investigator;
- They are available for all the visits scheduled in the study.
Exclusion criteria:
Subjects are not to be enrolled into the study if:
- They have a history of rabies immunization;
- They have an acute infectious disease at the time of study entry;
- They are under treatment with parenteral and/or oral steroids, immunosuppressive drugs, phenytoin or other specific anti-inflammatory drugs, or have taken chloroquine during the two month period before enrolment;
- They have a known immunodeficiency or an autoimmune disease;
- They have a known hypersensitivity to neomycin, tetracycline or amphotericin-B;
- They have planned surgery during the first study period (49 days);
- They are participating in any other trial of an investigational agent;
- They have any condition which in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- The family plans to leave the area of the study site before the end of the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 2 primary ID doses
two doses of rabies vaccines given intradermally on days 0 and 28
|
intradermal vaccination
Other Names:
|
|
EXPERIMENTAL: 3 primary ID doses
three doses of rabies vaccines given intradermally on days 0, 7, and 28
|
intradermal vaccination
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rabies virus neuralizing antibody, assessed by RFFIT
Time Frame: seven days after the first booster dose
|
rabies virus neuralizing antibody concentrations were measured in serum samples using the rapid fluorescent focus inhibition test (RFFIT)
|
seven days after the first booster dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rabies virus neuralizing antibody, assessed by RFFIT
Time Frame: one year after the first booster dose
|
rabies virus neuralizing antibody concentrations were measured in serum samples using the rapid fluorescent focus inhibition test (RFFIT)
|
one year after the first booster dose
|
|
rabies virus neuralizing antibody, assessed by RFFIT
Time Frame: immediately before administration of the first booster dose
|
rabies virus neuralizing antibody concentrations were measured in serum samples using the rapid fluorescent focus inhibition test (RFFIT)
|
immediately before administration of the first booster dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Thavatchai Kamoltham, MD, Provincial PHO
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- I49P1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.